{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:04:29Z","timestamp":1790687069045,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treatment options for Ankylosing Spondylitis (AS) are still limited. The T helper cell 17 (Th17) pathway has emerged as a major driver of disease pathogenesis and a good treatment target. Janus kinases (JAK) are key transducers of cytokine signals in Th17 cells and therefore promising targets for the treatment of AS. Here we investigate the therapeutic potential of four different JAK inhibitors on cells derived from AS patients and healthy controls, cultured<jats:italic>in-vitro<\/jats:italic>under Th17-promoting conditions. Levels of IL-17A, IL-17F, IL-22, GM-CSF and IFN\u03b3 were assessed by ELISA and inhibitory effects were investigated with Phosphoflow. JAK1\/2\/3 and TYK2 were silenced in CD4+ T cells with siRNA and effects analyzed by ELISA (IL-17A, IL-17F and IL-22), Western Blot, qPCR and Phosphoflow.<jats:italic>In-vitro<\/jats:italic>inhibition of CD4+ T lymphocyte production of multiple Th17 cytokines (IL-17A, IL-17F and IL-22) was achieved with JAK inhibitors of differing specificity, as well as by silencing of<jats:italic>JAK1-<\/jats:italic><jats:italic>3<\/jats:italic>and<jats:italic>Tyk2<\/jats:italic>, without impacting on cell viability or proliferation. Our preclinical data suggest JAK inhibitors as promising candidates for therapeutic trials in AS, since they can inhibit multiple Th17 cytokines simultaneously. Improved targeting of TYK2 or other JAK isoforms may confer tailored effects on Th17 responses in AS.<\/jats:p>","DOI":"10.1038\/s41598-018-34026-1","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T13:54:42Z","timestamp":1539784482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases"],"prefix":"10.1038","volume":"8","author":[{"given":"Ariane","family":"Hammitzsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2444-6050","authenticated-orcid":false,"given":"Jelle","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-3754","authenticated-orcid":false,"given":"M. Hussein","family":"Al-Mossawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ridley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Doig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Skapenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bowness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"issue":"9","key":"34026_CR1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.22831","volume":"68","author":"Carmen Stolwijk","year":"2016","unstructured":"Stolwijk, C., van Onna, M., Boonen, A. & van Tubergen, A. The global prevalence of spondyloarthritis: A systematic review and meta-regression analysis. Arthritis Care Res (Hoboken), https:\/\/doi.org\/10.1002\/acr.22831 (2015).","journal-title":"Arthritis Care & Research"},{"key":"34026_CR2","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados, M. & Baeten, D. Spondyloarthritis. Lancet 377, 2127\u20132137, https:\/\/doi.org\/10.1016\/S0140-6736(11)60071-8 (2011).","journal-title":"Lancet"},{"key":"34026_CR3","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde, D. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54, 2136\u20132146, https:\/\/doi.org\/10.1002\/art.21913 (2006).","journal-title":"Arthritis Rheum"},{"key":"34026_CR4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde, D. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52, 582\u2013591, https:\/\/doi.org\/10.1002\/art.20852 (2005).","journal-title":"Arthritis Rheum"},{"key":"34026_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe, R. et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 73, 39\u201347, https:\/\/doi.org\/10.1136\/annrheumdis-2013-204231 (2014).","journal-title":"Ann Rheum Dis"},{"key":"34026_CR6","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.4049\/jimmunol.1002653","volume":"186","author":"P Bowness","year":"2011","unstructured":"Bowness, P. et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol 186, 2672\u20132680, https:\/\/doi.org\/10.4049\/jimmunol.1002653 (2011).","journal-title":"J Immunol"},{"key":"34026_CR7","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","volume":"60","author":"H Shen","year":"2009","unstructured":"Shen, H., Goodall, J. C. & Hill Gaston, J. S. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 60, 1647\u20131656, https:\/\/doi.org\/10.1002\/art.24568 (2009).","journal-title":"Arthritis Rheum"},{"key":"34026_CR8","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten, D. et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 373, 2534\u20132548, https:\/\/doi.org\/10.1056\/NEJMoa1505066 (2015).","journal-title":"N Engl J Med"},{"key":"34026_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy, D., Hermann, K. G., Callhoff, J., Listing, J. & Sieper, J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73, 817\u2013823, https:\/\/doi.org\/10.1136\/annrheumdis-2013-204248 (2014).","journal-title":"Ann Rheum Dis"},{"key":"34026_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/ng.513","volume":"42","author":"C Australo-Anglo-American Spondyloart","year":"2010","unstructured":"Australo-Anglo-American Spondyloarthritis, C. et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 42, 123\u2013127, https:\/\/doi.org\/10.1038\/ng.513 (2010).","journal-title":"Nat Genet"},{"key":"34026_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi, K., Laurence, A. & O\u2019Shea, J. J. Janus kinases in immune cell signaling. Immunol Rev 228, 273\u2013287, https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00754.x (2009).","journal-title":"Immunol Rev"},{"key":"34026_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop, K. L. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13, 234\u2013243, https:\/\/doi.org\/10.1038\/nrrheum.2017.23 (2017).","journal-title":"Nat Rev Rheumatol"},{"key":"34026_CR13","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/art.34329","volume":"64","author":"K Maeshima","year":"2012","unstructured":"Maeshima, K. et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 64, 1790\u20131798, https:\/\/doi.org\/10.1002\/art.34329 (2012).","journal-title":"Arthritis Rheum"},{"key":"34026_CR14","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1136\/annrheumdis-2016-211046","volume":"76","author":"SK Raychaudhuri","year":"2017","unstructured":"Raychaudhuri, S. K., Abria, C. & Raychaudhuri, S. P. Regulatory role of the JAK STAT kinase signalling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis. Ann Rheum Dis 76, e36, https:\/\/doi.org\/10.1136\/annrheumdis-2016-211046 (2017).","journal-title":"Ann Rheum Dis"},{"key":"34026_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester, G. R. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 451\u2013460, https:\/\/doi.org\/10.1016\/S0140-6736(12)61424-X (2013).","journal-title":"Lancet"},{"key":"34026_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1126\/science.1087061","volume":"302","author":"PS Changelian","year":"2003","unstructured":"Changelian, P. S. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875\u2013878, https:\/\/doi.org\/10.1126\/science.1087061 (2003).","journal-title":"Science"},{"key":"34026_CR17","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde, D. et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 76, 1340\u20131347, https:\/\/doi.org\/10.1136\/annrheumdis-2016-210322 (2017).","journal-title":"Ann Rheum Dis"},{"key":"34026_CR18","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi, K. et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186, 4234\u20134243, https:\/\/doi.org\/10.4049\/jimmunol.1003668 (2011).","journal-title":"J Immunol"},{"key":"34026_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26, 127\u2013132, https:\/\/doi.org\/10.1038\/nbt1358 (2008).","journal-title":"Nat Biotechnol"},{"key":"34026_CR20","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","volume":"168","author":"C Parham","year":"2002","unstructured":"Parham, C. et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168, 5699\u20135708 (2002).","journal-title":"J Immunol"},{"key":"34026_CR21","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/ng.2667","volume":"45","author":"International Genetics of Ankylosing Spondylitis, C","year":"2013","unstructured":"International Genetics of Ankylosing Spondylitis, C. et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 45, 730\u2013738, https:\/\/doi.org\/10.1038\/ng.2667 (2013).","journal-title":"Nat Genet"},{"key":"34026_CR22","doi-asserted-by":"publisher","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","volume":"8","author":"CA Dendrou","year":"2016","unstructured":"Dendrou, C. A. et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med 8, 363ra149, https:\/\/doi.org\/10.1126\/scitranslmed.aag1974 (2016).","journal-title":"Sci Transl Med"},{"key":"34026_CR23","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.immuni.2012.08.025","volume":"37","author":"T Griseri","year":"2012","unstructured":"Griseri, T., McKenzie, B. S., Schiering, C. & Powrie, F. Dysregulated hematopoietic stem and progenitor cell activity promotes interleukin-23-driven chronic intestinal inflammation. Immunity 37, 1116\u20131129, https:\/\/doi.org\/10.1016\/j.immuni.2012.08.025 (2012).","journal-title":"Immunity"},{"key":"34026_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/ni.2031","volume":"12","author":"M El-Behi","year":"2011","unstructured":"El-Behi, M. et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12, 568\u2013575, https:\/\/doi.org\/10.1038\/ni.2031 (2011).","journal-title":"Nat Immunol"},{"key":"34026_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01771-2","volume":"8","author":"MH Al-Mossawi","year":"2017","unstructured":"Al-Mossawi, M. H. et al. Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. Nat Commun 8, 1510, https:\/\/doi.org\/10.1038\/s41467-017-01771-2 (2017).","journal-title":"Nat Commun"},{"key":"34026_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jaut.2005.02.001","volume":"24","author":"SA Litherland","year":"2005","unstructured":"Litherland, S. A. et al. Signal transduction activator of transcription 5 (STAT5) dysfunction in autoimmune monocytes and macrophages. J Autoimmun 24, 297\u2013310, https:\/\/doi.org\/10.1016\/j.jaut.2005.02.001 (2005).","journal-title":"J Autoimmun"},{"key":"34026_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep24491","volume":"6","author":"C Lochmatter","year":"2016","unstructured":"Lochmatter, C. et al. Integrative Phosphoproteomics Links IL-23R Signaling with Metabolic Adaptation in Lymphocytes. Sci Rep 6, 24491, https:\/\/doi.org\/10.1038\/srep24491 (2016).","journal-title":"Sci Rep"},{"key":"34026_CR28","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.178.8.4901","volume":"178","author":"AN Mathur","year":"2007","unstructured":"Mathur, A. N. et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol 178, 4901\u20134907 (2007).","journal-title":"J Immunol"},{"key":"34026_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nm1585","volume":"13","author":"A Amadi-Obi","year":"2007","unstructured":"Amadi-Obi, A. et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1. Nat Med 13, 711\u2013718, https:\/\/doi.org\/10.1038\/nm1585 (2007).","journal-title":"Nat Med"},{"key":"34026_CR30","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop, K. L. et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66, 2675\u20132684, https:\/\/doi.org\/10.1002\/art.38745 (2014).","journal-title":"Arthritis Rheumatol"},{"key":"34026_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0092-8674(92)90105-L","volume":"70","author":"L Velazquez","year":"1992","unstructured":"Velazquez, L., Fellous, M., Stark, G. R. & Pellegrini, S. A protein tyrosine kinase in the interferon alpha\/beta signaling pathway. Cell 70, 313\u2013322 (1992).","journal-title":"Cell"},{"key":"34026_CR32","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1084\/jem.20140280","volume":"212","author":"AY Kreins","year":"2015","unstructured":"Kreins, A. Y. et al. Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med 212, 1641\u20131662, https:\/\/doi.org\/10.1084\/jem.20140280 (2015).","journal-title":"J Exp Med"},{"key":"34026_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz, D. M., Bonelli, M., Gadina, M. & O\u2019Shea, J. J. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12, 25\u201336, https:\/\/doi.org\/10.1038\/nrrheum.2015.167 (2016).","journal-title":"Nat Rev Rheumatol"},{"key":"34026_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature10098","volume":"473","author":"B Schwanhausser","year":"2011","unstructured":"Schwanhausser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337\u2013342, https:\/\/doi.org\/10.1038\/nature10098 (2011).","journal-title":"Nature"},{"key":"34026_CR35","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.1074\/jbc.M114.619502","volume":"290","author":"JS Tokarski","year":"2015","unstructured":"Tokarski, J. S. et al. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. J Biol Chem 290, 11061\u201311074, https:\/\/doi.org\/10.1074\/jbc.M114.619502 (2015).","journal-title":"J Biol Chem"},{"key":"34026_CR36","doi-asserted-by":"crossref","first-page":"67.12","DOI":"10.4049\/jimmunol.194.Supp.67.12","volume":"194","author":"C Masse","year":"2015","unstructured":"Masse, C. et al. Identification of highly potent and selective Tyk2 inhibitors for the treatment of autoimmune diseases through structure-based drug design (THER2P.961). The Journal of Immunology 194, 67.12 (2015).","journal-title":"The Journal of Immunology"},{"key":"34026_CR37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2174\/0929866520666131203101841","volume":"21","author":"MG Works","year":"2014","unstructured":"Works, M. G. et al. Design of a peptide inhibitor of tyrosine kinase 2. Protein Pept Lett 21, 419\u2013425 (2014).","journal-title":"Protein Pept Lett"},{"key":"34026_CR38","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone, E. C. et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74, 333\u2013340, https:\/\/doi.org\/10.1136\/annrheumdis-2014-206478 (2015).","journal-title":"Ann Rheum Dis"},{"key":"34026_CR39","unstructured":"Lories, R. et al. Tofacitinib Inhibits Inflammation and New Bone Formation in Murine Spondyloarthritis but Does Not Adversely Inhibit Normal Human MSC Function. Arthritis Rheumatol 67 (2015)."},{"key":"34026_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit, M. et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70, 25\u201331, https:\/\/doi.org\/10.1136\/ard.2010.133645 (2011).","journal-title":"Ann Rheum Dis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34026-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T02:46:41Z","timestamp":1693968401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34026-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["34026"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-34026-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"assertion":[{"value":"19 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15645"}}